Clinical Trial

Effects of DHA in Patients With Multiple Sclerosis

Study acronym: DHAME

Enrolling by Invitation

Record status

This record was last updated January 16, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Summary

This clinical trial will investigate the effects of combining therapeutic exercise with DHA supplementation in 100 patients with multiple sclerosis using a randomized controlled design. Participants, diagnosed according to the McDonald criteria, will undergo functional, cognitive, fatigue, and quality-of-life assessments through tools such as the EDSS, BRB-N, MFIS, EVA-f, and MSQoL-54. Physiological evaluations will include infrared thermography, isokinetic strength testing, perceived exertion (Modified Borg Scale), balance (Timed Up and Go), lower-limb power (Sit-to-Stand app), and handgrip strength. The study hypothesizes that this combined intervention will improve motor function, cognition, fatigue management, and overall quality of life by enhancing neuromuscular activation and metabolic efficiency.

Trial Details

NCT Number	NCT07346703
Lead Sponsor	Francisco Javier Martínez Noguera
Conditions	Multiple Sclerosis, Performance Enhancement, Supplemental Nutrition Assistance Program Education, Strength Outcomes, Function Improvement, Intervention Study
Enrollment	100 participants
Start Date	2026-01
Primary Completion	2026-06 (estimated)
Study Completion	2026-07 (estimated)
Updated on ClinicalTrials.gov	2026-01-16